ArticleGut pathogens2025
Extracts from Plectranthus asirensis and Premna resinosa inhibit Helicobacter pylori-induced epithelial cell damage, DNA double-strand breaks and inflammation.
Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori infection is a major global health issue associated with chronic gastritis, peptic ulcers, and gastric cancer. Due to the increasing resistance of H. pylori to conventional antibiotics, there is growing interest in researching alternative therapeutic agents, particularly those from medicinal plants.
methodsPreparation and purification of extracts from two plant species, Plectranthus asirensis and Premna resinosa, were performed by cold maceration. The anti-microbial activity of two extracts was then evaluated against H. pylori to determine the minimum inhibitory concentration (MIC). The activity of the extracts was further analyzed by electron microscopy, bacterial cell lysis and Western blotting. The effects on AGS gastric epithelial cells upon infection were monitored by cell scattering, cell vacuolization, DNA damage analysis, NF-κB reporter assay and chemokine ELISA.
resultsWe determined the MIC of P. asirensis and P. resinosa extracts on treated H. pylori as 200 µg/mL and 35 µg/mL, respectively. Electron microscopy showed severe deformation of the bacterial cells. We obtained no bacterial cell lysis and only minimal changes in protein expression levels of the virulence factors CagA, CagY, HopQ, urease, and flagellin. However, we found that cleavage of the vacuolating cytotoxin VacA p98 pro-form to the p88 active form was significantly downregulated. The enzymatic urease activity was also impaired by the addition of both extracts, while the proteolytic activity of serine protease HtrA was not affected. Infection of AGS cells in the presence of both extracts revealed that type IV secretion system (T4SS)-dependent CagA injection, cell scattering and motility, as well as VacA-dependent cellular vacuolation were completely inhibited. Furthermore, H. pylori-induced pro-inflammatory transcription factor NF-κB and interleukin-8 release were also significantly downregulated. Finally, both extracts prevented T4SS-induced DNA double-strand breaks (DSBs) and chromosomal fragmentation in the nuclei of host cells.
conclusionsTaken together, we have discovered natural compounds of P. asirensis and P. resinosa that exhibit potent anti-H. pylori activities, not only inhibiting bacterial growth, but also suppressing key virulence mechanisms involved in epithelial cell damage, inflammation and genomic instability. These extracts are promising candidates for future therapeutic applications in patients, which could help minimizing H. pylori infections and gastric cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.